SAN FRANCISCO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- A new securities class-action lawsuit has been filed against SelectQuote, Inc. (NYSE: SLQT) and its executives after the U.S. Department of Justice (DOJ) announced its intervention in a separate lawsuit against the company. This federal involvement triggered a sharp 19% decline in SelectQuote’s stock price on May 1, 2025, leading to significant investor losses. The lawsuit, known as Pahlkotter v. SelectQuote, Inc. et al., is on behalf of investors who purchas ...

Core Viewpoint - A securities class action lawsuit has been filed against SelectQuote following the U.S. Department of Justice's intervention in a separate lawsuit, leading to a significant 19% drop in the company's stock price on May 1, 2025 [1][4]. Group 1: Lawsuit Details - The class action, Pahlkotter v. SelectQuote, Inc. et al., seeks to represent investors who acquired SelectQuote securities between September 9, 2020, and May 1, 2025 [2]. - The lead plaintiff deadline for the lawsuit is set for October 10, 2025 [2]. Group 2: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements regarding its business practices, particularly in its Medicare Advantage sales [3]. - The DOJ claims that from 2016 to at least 2021, SelectQuote received "tens of millions of dollars" in illegal kickbacks for directing Medicare beneficiaries to specific plans, contradicting its claims of providing unbiased advice [3][8]. - The company allegedly discriminated against less profitable beneficiaries and directed customers to the highest-paying plans, which raises concerns about compliance with applicable laws [3][8]. Group 3: Impact on Stock and Investor Sentiment - Following the announcement of the DOJ's involvement and the class action lawsuit, SelectQuote's stock price has continued to decline, indicating a significant impact on the company's market value [4]. - Hagens Berman is investigating the extent to which SelectQuote's alleged practices may have inflated its financial results, leading to investor losses [7][9].

Hagens Berman urges SelectQuote investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Class Period: Sept. 9, 2020 – May 1, 2025 Lead Plaintiff Deadline: Oct. 10, 2025 Visit: www.hbsslaw.com/investor-fraud/slqt Contact the Firm Now: [email protected] 844-916-0895 SAN FRANCISCO, Aug. 13, 2025 /PRNewswire/ -- After investors in SelectQuote (NYSE: SLQT) saw the price of their s ...

Core Viewpoint - SelectQuote Inc. is facing significant investor pressure due to disappointing quarterly results and ongoing legal issues, leading to a substantial decline in its stock price [1][3]. Financial Performance - For the quarter ended March 2025, SelectQuote reported earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share [2]. - The company posted revenues of $408.16 million, falling short of the Zacks Consensus Estimate of $417.01 million by 2.12% [2]. Legal Issues - The U.S. Department of Justice (DOJ) announced a lawsuit against SelectQuote and several major health insurers on May 1, 2025, alleging violations of the False Claims Act related to the marketing of Medicare Advantage plans [3][4]. - The lawsuit claims that from 2016 to at least 2021, SelectQuote and other brokers were incentivized to steer beneficiaries toward high-commission plans, potentially disregarding the suitability of those plans [4]. Investor Sentiment - The combination of a weaker-than-expected earnings report and serious legal allegations has heightened concerns regarding SelectQuote's financial stability and operational integrity [5]. - Hagens Berman is investigating potential violations of U.S. securities laws and is encouraging investors who suffered losses to come forward [2][5].

Core Viewpoint - SelectQuote Inc. is facing significant investor pressure due to a sharp decline in share prices following disappointing quarterly earnings and ongoing legal issues related to alleged violations of the False Claims Act [1][3]. Financial Performance - For the quarter ended March 2025, SelectQuote reported earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share [2]. - The company posted revenues of $408.16 million, falling short of the Zacks Consensus Estimate of $417.01 million by 2.12% [2]. Legal Issues - The U.S. Department of Justice (DOJ) announced a lawsuit on May 1, 2025, alleging that SelectQuote and other health insurers violated the False Claims Act in their marketing of Medicare Advantage plans [3][4]. - The lawsuit claims that from 2016 to at least 2021, SelectQuote received significant payments from insurers for Medicare Advantage enrollments, but allegedly steered beneficiaries toward higher-commission plans, disregarding their suitability [4]. Investor Sentiment - The combination of poor earnings and serious legal allegations has heightened concerns regarding SelectQuote's financial stability and operational integrity [5]. - Hagens Berman, a law firm investigating SelectQuote, emphasizes that the recent earnings figures raise existing concerns about the company's alleged steering tactics in light of the DOJ's allegations [5].

Core Viewpoint - SelectQuote Inc. is facing significant investor pressure due to a sharp decline in share prices following disappointing quarterly results and ongoing legal issues related to alleged violations of the False Claims Act [1][3]. Financial Performance - For the quarter ended March 2025, SelectQuote reported earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share [2]. - The company posted revenues of $408.16 million, falling short of the Zacks Consensus Estimate of $417.01 million by 2.12% [2]. Legal Issues - The U.S. Department of Justice (DOJ) announced a lawsuit on May 1, 2025, alleging that SelectQuote and other major health insurers violated the False Claims Act in their marketing of Medicare Advantage plans [3][4]. - The lawsuit claims that from 2016 to at least 2021, SelectQuote received significant payments from insurers for Medicare Advantage enrollments, but allegedly steered beneficiaries toward higher-commission plans, disregarding their suitability [4]. Investor Sentiment - The combination of a disappointing earnings report and serious legal allegations has heightened concerns regarding SelectQuote's financial stability and operational integrity [5]. - Hagens Berman is investigating potential violations of U.S. securities laws and is encouraging investors who have suffered losses to come forward [2][5].

Core Insights - Sutter Health and Alignment Healthcare have renewed their agreement, ensuring continued in-network access for Alignment Healthcare members to Sutter's comprehensive care network in Northern California [1][2] Group 1: Agreement Details - The renewed agreement applies to Alignment Healthcare members enrolled in Sutter Advantage HMO and My Choice PPO health plans, focusing on providing access to care for high-risk individuals with chronic conditions [2][4] - The collaboration aims to enhance patient experience and lower total care costs by leveraging the strengths of both organizations [3][4] Group 2: Expansion Plans - Sutter Health plans to open over 27 new ambulatory care sites, 27 urgent care centers, and 22 ambulatory surgery centers starting in 2025, addressing the ongoing national challenge of healthcare access [3] Group 3: Medicare Advantage Benefits - Medicare Advantage plans offer additional benefits beyond Original Medicare, including care coordination, disease management, in-home support, and limited annual out-of-pocket costs, which may lead to better health outcomes [5] Group 4: Company Profiles - Sutter Health is a not-for-profit healthcare system serving nearly 3.5 million patients with over 57,000 employees and 12,000+ affiliated physicians, focused on expanding care accessibility [6] - Alignment Health aims to empower seniors through high-quality, low-cost care, utilizing a customized care model and technology platform, AVA, to deliver coordinated care [8]